Key result
Women account for approximately 60% of syncope and palpitation cohorts and face higher risks of proarrhythmia with QT-prolonging medications and complications from invasive cardiac procedures.
The evaluation of syncope and palpitations in women requires a problem-specific approach centered on rhythm documentation, with special consideration for gender-related differences in treatment safety, including higher risks of proarrhythmia and procedural complications.
Answers are grounded in this paper and cite their sources.
Warrants caution with QT-prolonging agents and procedures in women; leaves open efficacy of tailored approaches in prospective trials.
Syncope and palpitations are common complaints that all physicians confront during daily clinical practice. Single center and multicenter cohort studies have found that syncope accounts for 1%-3% of emergency department evaluations and that palpitations are the primary symptom for approximately 16% of patients who arrive at an outpatient clinic with a cardiac complaint. For both conditions, women make up approximately 60% of the cohorts. In general, the evaluation of both syncope and palpitations can be challenging because of the heterogeneity of causes and, consequently, the variability of clinical outcomes, ranging from a single isolated event with no effect on morbidity and mortality to the first sign of a potentially life-threatening problem and sudden cardiac death. For all women with syncope or palpitations, the history, physical examination, and a baseline electrocardiogram (ECG) form the basis of the initial workup and focus on identifying patients with cardiovascular abnormalities who are at the highest risk for sudden cardiac death. More advanced tests must be chosen using a problem-specific approach, but generally, documentation of the cardiac rhythm during symptoms is critical for all patients with syncope or palpitations. Although the diagnostic testing strategy is generally similar for men and women, gender-related differences in treatment response have been identified. Antiarrhythmic medications, such as dofetilide and sotalol, that prolong the QT interval are more likely to be associated with proarrhythmia in women. In addition, higher complication rates for invasive cardiac procedures, such as device implantation, are observed in women.
No takes yet. Share an insight, caveat, or question.
Misiri et al. (2011) conducted a review in Syncope and palpitations. Women account for approximately 60% of syncope and palpitation cohorts and face higher risks of proarrhythmia with QT-prolonging medications and complications from invasive cardiac procedures.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: